BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blatt J, Corey SJ. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov Today 2013;18:4-10. [PMID: 22835502 DOI: 10.1016/j.drudis.2012.07.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Papaioannou M, Mylonas I, Kast RE, Brüning A. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition. Oncoscience 2014;1:21-9. [PMID: 25593981 DOI: 10.18632/oncoscience.5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
2 Rumore MM. Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks. J Pediatr Pharmacol Ther 2016;21:36-53. [PMID: 26997928 DOI: 10.5863/1551-6776-21.1.36] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
3 Bernauer C, Man YKS, Chisholm JC, Lepicard EY, Robinson SP, Shipley JM. Hypoxia and its therapeutic possibilities in paediatric cancers. Br J Cancer 2021;124:539-51. [PMID: 33106581 DOI: 10.1038/s41416-020-01107-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 2014;11:413-31. [PMID: 24913374 DOI: 10.1038/nrclinonc.2014.89] [Cited by in Crossref: 182] [Cited by in F6Publishing: 176] [Article Influence: 22.8] [Reference Citation Analysis]
5 Szabo C. Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat Rev Drug Discov 2016;15:185-203. [PMID: 26678620 DOI: 10.1038/nrd.2015.1] [Cited by in Crossref: 261] [Cited by in F6Publishing: 234] [Article Influence: 37.3] [Reference Citation Analysis]
6 Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology--patient and health systems opportunities. Nat Rev Clin Oncol 2015;12:732-42. [PMID: 26483297 DOI: 10.1038/nrclinonc.2015.169] [Cited by in Crossref: 152] [Cited by in F6Publishing: 142] [Article Influence: 21.7] [Reference Citation Analysis]
7 Montalvo-Casimiro M, González-Barrios R, Meraz-Rodriguez MA, Juárez-González VT, Arriaga-Canon C, Herrera LA. Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy. Front Oncol 2020;10:605386. [PMID: 33312959 DOI: 10.3389/fonc.2020.605386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Wolter JK, Wolter NE, Blanch A, Partridge T, Cheng L, Morgenstern DA, Podkowa M, Kaplan DR, Irwin MS. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget 2014;5:161-72. [PMID: 24389287 DOI: 10.18632/oncotarget.1083] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
9 Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014;19:637-44. [PMID: 24239728 DOI: 10.1016/j.drudis.2013.11.005] [Cited by in Crossref: 214] [Cited by in F6Publishing: 166] [Article Influence: 23.8] [Reference Citation Analysis]
10 Kelly DP, Blatt J. Serendipitous drug repurposing through social media. Drug Discov Today 2019;24:1321-3. [PMID: 31102729 DOI: 10.1016/j.drudis.2019.05.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 McCabe B, Liberante F, Mills KI. Repurposing medicinal compounds for blood cancer treatment. Ann Hematol 2015;94:1267-76. [PMID: 26048243 DOI: 10.1007/s00277-015-2412-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
12 Kim U, Kim CY, Lee JM, Ryu B, Kim J, Shin C, Park JH. Pimozide Inhibits the Human Prostate Cancer Cells Through the Generation of Reactive Oxygen Species. Front Pharmacol 2019;10:1517. [PMID: 32009948 DOI: 10.3389/fphar.2019.01517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. J Nat Prod 2014;77:703-23. [PMID: 24499205 DOI: 10.1021/np5000796] [Cited by in Crossref: 161] [Cited by in F6Publishing: 142] [Article Influence: 20.1] [Reference Citation Analysis]
14 Blatt J, Farag S, Corey SJ, Sarrimanolis Z, Muratov E, Fourches D, Tropsha A, Janzen WP. Expanding the scope of drug repurposing in pediatrics: the Children's Pharmacy Collaborative. Drug Discov Today 2014;19:1696-8. [PMID: 25149597 DOI: 10.1016/j.drudis.2014.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
15 Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 2015;20:1027-34. [PMID: 25975957 DOI: 10.1016/j.drudis.2015.05.001] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 18.4] [Reference Citation Analysis]
16 Delavan B, Roberts R, Huang R, Bao W, Tong W, Liu Z. Computational drug repositioning for rare diseases in the era of precision medicine. Drug Discov Today 2018;23:382-94. [PMID: 29055182 DOI: 10.1016/j.drudis.2017.10.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
17 Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Mol Cancer Ther 2017;16:397-407. [PMID: 27980103 DOI: 10.1158/1535-7163.MCT-16-0588] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
18 Shen M, Asawa R, Zhang YQ, Cunningham E, Sun H, Tropsha A, Janzen WP, Muratov EN, Capuzzi SJ, Farag S, Jadhav A, Blatt J, Simeonov A, Martinez NJ. Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. Oncotarget 2018;9:4758-72. [PMID: 29435139 DOI: 10.18632/oncotarget.23462] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
19 Pasquier E, André N, Street J, Chougule A, Rekhi B, Ghosh J, Philip DSJ, Meurer M, MacKenzie KL, Kavallaris M, Banavali SD. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. EBioMedicine 2016;6:87-95. [PMID: 27211551 DOI: 10.1016/j.ebiom.2016.02.026] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 10.2] [Reference Citation Analysis]
20 Salazar BM, Balczewski EA, Ung CY, Zhu S. Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology. Int J Mol Sci 2016;18:E37. [PMID: 28035989 DOI: 10.3390/ijms18010037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
21 Verbaanderd C, Rooman I, Meheus L, Huys I. On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients. Front Pharmacol 2019;10:1664. [PMID: 32076405 DOI: 10.3389/fphar.2019.01664] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
22 Chen JJ, Cai N, Chen GZ, Jia CC, Qiu DB, Du C, Liu W, Yang Y, Long ZJ, Zhang Q. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma. Oncotarget 2017;8:17593-609. [PMID: 26061710 DOI: 10.18632/oncotarget.4307] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]